DexCom showed strong growth, margin expansion, and Stelo's OTC launch unlocked new markets despite competitive and regulatory ...
On September 19, William Blair analyst Brandon Vazquez maintained their bullish stance on the company’s stock, giving a “Buy” rating. The analyst’s rating is backed by a combination of factors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback